Posted by Michael Wonder on 27 Mar 2021
FDA approves first cell-based gene therapy for adult patients with multiple myeloma
27 March 2021 - The U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.
Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma.
